

台灣神經內分泌腫瘤學會 2024 春季會

時間：2024/04/27 (星期六) 13:30~17:10

地點：蓮潭國際會館106會議室 (地址：高雄市左營區崇德路801號)

報到時間：13:00~

		Speaker	Moderator
13:30~13:40	致詞	陳立宗 理事長	
13:40~14:20	Current treatment of NETS, focus on G2/G3	陳彥仰 醫師 高雄長庚 血液腫瘤科	黃燦龍 教授
14:20~15:00	2024 ENETS update Sponsored by IPSEN	陳明晃 醫師 北榮 腫瘤醫學部	顏家瑞 教授
15:00~15:20	Discussion		
15:20~15:30	Coffee break		
15:30~16:10	The new page of NET treatment with PRRT - How to optimize the solution with clinical experience Sponsored by Novartis	杜政勳 醫師 高醫 血液腫瘤內科	白禮源 主任
16:10~16:50	教育演講 Advances in the Management and Treatment of Pheochromocytoma and Paraganglioma (PPGLs)	林家宏 醫師 台大 內分泌科	洪崇傑 教授
16:50~17:10	Discussion		
17:30~	理監事會議		

學會教育積分：(申請中)

台灣外科醫學會	台灣內科醫學會
台灣消化系外科醫學會	台灣消化系醫學會
台灣內視鏡外科醫學會	台灣消化系內視鏡醫學會
中華民國內分泌學會	中華民國癌症醫學會
中華民國核醫學學會	

陳彥仰 醫師

現職：

高雄長庚血液腫瘤科科主任

高雄長庚血液腫瘤科 主治醫師

學歷：

長庚大學 臨床醫學研究所 博士

台北醫學大學 醫學系

經歷：

高雄長庚醫院內科部 住院醫師

高雄長庚血液腫瘤科 住院總醫師

高雄長庚血液腫瘤科 主治醫師

學會與認證：

中華民國癌症醫學會

台灣內科醫學會

論文及期刊發表：

Chen YY, Yeh CN*, Tseng JH, Chen JS, Chen TW, Tsai CY, Cheng CT, Jan YY, Chen MF. Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing kit : A decade experience from Taiwan. *Translational oncology*. 2011 ; 4:328-325. (SCI; IF=3.393; *Oncology* 97/184)

Jen-Shi Chen, Yen-Yang Chen, Jen-Sheng Huang, Kun-Yun Yeh, Ping-Tsung Chen, Wen-Chi Shen, Hung-Chih Hsu, Yung-Chung Lin and Hung-Ming Wang. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. *Gastric cancer*. 2012;15:49-55. (SCI; IF=1.897; *Gastroenterology & hepatology* 44/71)

Yen-Yang Chen, Chun-Nan Yeh*, Chi-Tung Cheng, Tsung-Wen Chen, Kun-Ming Rau, Yi-Yin Jan, Miin-Fu Chen. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. *World journal of gastroenterology*. 2011;17:2113-2119. (SCI; IF=1.897; *Gastroenterology & hepatology* 35/71)

Wu chi ache, Tai-jan chiu, Meng-Chih Lin, Jui-Ling Wang, Kun ming Rau, Chen YY, Huang CH*. Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : A retrospective analysis. 2011;27:157-164

Chen YH, Lu HI, Huang CH, Rau KM, Chiu YC, Wang YM, Chen YY, Liu CT, Li SH*. The use of trimodality treatment of locally advanced resectable esophageal squamous cell carcinoma: a single institute experience in southern Taiwan. *Journal of Cancer Research and Practice*. 2011; Oct 27(5): 200-210

Curriculum Vitae

Name :

Ming-Huang Chen MD., Ph.D.

Business Address :

No. 201, Section 2, Shih-Pai Rd, Taipei, 11217, Taiwan

Professional Experience :

2023-present, Director, Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital

2021-present, Secretary General, Taiwan Oncology Society

2020-2023, Director of Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital

2017-2019, Attending physician, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2021, Professor, National Yang Ming Chiao Tung University, Taiwan

2017, Visitor, National Cancer Center, Tokyo, Japan

2011, Visitor, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (USA)

Education and medical Training :

<Education>

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

<Medical training>

2005-2008 Fellowship in Division of Hematology & Oncology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2002-2005 Residency, Department of Internal Medicine

2001-2002 Internship, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

Board Certification :

Board of Oncology

Board of Hematology

Board of the Internal Medicine

Board of Hospice care

Board of Bone Marrow Transplantation

Memberships :

Taiwan Oncology Society
The Society of Internal Medicine
American Society of Clinical Oncology
European Neuroendocrine Tumor Society

Study Experiences

IIT trial

1. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, **Chen MH**. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. *Clin Cancer Res*. 2022 Oct 3;28(19):4248-4257.

2. **Chen MH**, et al. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. *Medicine (Baltimore)*. 2016 Jan;95(3):e2565.

3. **Chen MH**, et al. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects with Poorly Differentiated Neuroendocrine Carcinomas, *Oncologist*. 2020 May;25(5):e782-e788

Publications (only first author or corresponding author):

Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DSS, Wu CE, Lai JI, Chang PMH, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, **Chen MH**. *PRKDC*: New Biomarker and Drug Target for Checkpoint Blockade Immunotherapy. *J Immunother Cancer*. 2020 Mar;8(1):e000485

Pan YR, Wu CE, Wang YC, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JCH, **Chen MH**[#] and Chun-Nan Yeh[#]. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response.. Accepted by *Clinical & Translational Immunology*
Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST). Might Be a More Promising Immune Biomarker in Colorectal Cancer. *Oncologist*. 2019 Dec;24(12):1534-1542.

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. *Clin Cancer Res*. 2016 Aug

15;22(16):4225-35.

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, **Chen MH***, **Yeh CN**. MET-ROn dual inhibitor, BMS-777607, suppresses cholangiocarcinoma cell growth, and MET-ROn upregulation indicates worse prognosis for intra-hepatic cholangiocarcinoma patients. *Oncol Rep*. 2018 Sep;40(3):1411-1421.

Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, **Chen MH**. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. *Int J Biol Sci*. 2016 Nov 25;12(12):1523-1532.

Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. *Oncotarget*. 2015 Sep 15;6(27):23594-608.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. *Oncotarget*. 2014;5:2372-89.

Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. *Ann Surg Oncol*. 2013;20:616-24.

Chen MH, Lin KJ, Yang WLR, Kao YW, Chen TW, Chao SC, Chang PMH, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CYF. Gene Expression-Based Chemical Genomics Identifies Heat Shock Protein 90 Inhibitors as Potential Therapeutic Drugs in Cholangiocarcinoma. *Cancer*. 2013;119:293-303.

Chen MH, Yeh YC, Shyr YM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PMH, Liu CY, Chen MH, Hsiao M, Huang CYF. Expression of Gremlin 1 Correlates with Increased Angiogenesis and Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. *Journal of Gastroenterology*. 2013;48:101-8.

Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. *PLoS One*. 2011;6:e27186.

Curriculum Vitae

杜政勳

現任

高雄醫學大學附設中和紀念醫院血液腫瘤內科 主治醫師

學歷

高雄醫學大學 臨床醫學研究所 碩士

高雄醫學大學 學士後醫學系 醫學士

經歷

2012.08.01~2013.07.31 高雄醫學大學附設中和紀念醫院 一般科住院醫師(PGY)

2013.08.01~2016.07.31 高雄醫學大學附設中和紀念醫院 內科部住院醫師

2016.08.01~2016.10.31 高雄醫學大學附設中和紀念醫院 內科部行政總醫師

2016.08.01~2018.07.31 高雄醫學大學附設中和紀念醫院 血液腫瘤內科研習醫師

2018.08.01~迄今 高雄醫學大學附設中和紀念醫院 血液腫瘤內科主治醫師

2021.08.02~2021.08.31 財團法人醫藥品查驗中心 研習(培訓)醫師

專科執照與學會

醫師高等考試合格(醫字第049226號)

台灣內科醫學會/內科專科醫師(內專醫字第010628號)

中華民國血液病學會/血液病專科醫師(中血專醫字108474)

中華民國癌症醫學會/腫瘤內科專科醫師(中腫內專醫證字第108002號)

中華民國血液及骨髓移植學會/血液及骨髓移植專科醫師(中血移專醫字108214號)

台灣臨床腫瘤醫學會/臨床腫瘤專科醫師(台臨腫專醫證字第207號)

台灣癌症安寧緩和醫學會/癌症安寧緩和專科醫師(癌安專字0000000185)

台灣肺癌研究學會/會員

台灣癌症研究學會/會員

Reward

高醫附院100學年度模範實習醫師 (2011)

高醫附院101學年度畢業後一般醫學訓練 評量考核優良 (2012)

高醫附院104學年度模範住院醫師 (2015)

高醫附院105學年度模範住院醫師 (2016)

高醫附院106學年度模範總住院醫師 (2017)

Publications

1. Tang SH, Lin MH, **Du JS**, Liu YC, Hsiao HH, Liu TC. IgG4-related disease with bone marrow involvement mimicking multiple myeloma. *Br J Haematol*. 2017 Jun;177(5):673.
2. **Du JS**, Lin CH, Wang HC, Hsiao HH. A case of recurrent angiosarcoma with isolated bone marrow metastasis presented as acute disseminated intravascular coagulation. *Kaohsiung J Med Sci* 2019 Apr; 35(4): 244-245.
3. Tsai YF, Yang CI, **Du JS**, Lin MH, Tang SH, Wang HC, Cho SF, Liu YC, Su YC, Dai CY, Hsiao HH. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. *PeerJ*. 2019 Sep 9;7:e7481.
4. **Du JS**, Cheng YT, Hsiao HH. A case of acute lymphoblastic leukemia with spontaneous tumor lysis syndrome after adenosine injection. *J Cancer Res Pract* 2019;6:197-9.
5. Liu YC, Lee CP, Yeh TJ, Gau YC, Hsieh CY, Ke YL, **Du JS**, Lin MH, Wang HC, Tang SH, Cho SF, Hsiao CE, Hsu JF, Hsiao SY, Hsu CM, Hsiao HH. Calreticulin Mutation Survey by High Resolution Melting Method Associated with Unique Presentations in Essential Thrombocytopenic Patients. *Mediterr J Hematol Infect Dis*. 2020 May 1;12(1):e2020022.
6. Chiu YY, Chen YH, Hsiao HH, **Du JS**. A rare patient with primary endogenous Aspergillus endophthalmitis. *J Microbiol Immunol Infect*. 2021 Jan 6:S1684-1182(21)00012-8. doi: 10.1016/j.jmii.2020.12.014. Epub ahead of print. PMID: 33454222.
7. Yeh TJ, Chan LP, Tsai HT, Hsu CM, Cho SF, Pan MR, Liu YC, Huang CJ, Wu CW, **Du JS**, Wang HC. The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience. *Biology (Basel)*. 2021 Feb 23;10(2):168. doi: 10.3390/biology10020168. PMID: 33672266.
8. **Du JS**, Yen CH, Hsu CM, Hsiao HH. Management of Myeloma Bone Lesions. *Int J Mol Sci*. 2021 Mar 25;22(7):3389. doi: 10.3390/ijms22073389. PMID: 33806209.
9. Chuang TM, Liu YC, Hsiao HH, Wang HC, **Du JS**, Yeh TJ, Gau YC, Ke YL, Yang CI, Lee CP, Hsu CM, Cho SF. Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. *Nutrients*. 2021 Sep 17;13(9):3243. doi: 10.3390/nu13093243. PMID: 34579119.
10. Wang HC, Chan LP, Wu CC, Hsiao HH, Liu YC, Cho SF, **Du JS**, Liu TC, Yang CH, Pan MR, Moi SH. Progression Risk Score Estimation Based on Immunostaining Data in Oral Cancer Using Unsupervised Hierarchical Clustering Analysis: A Retrospective Study in Taiwan. *J Pers Med*. 2021 Sep 13;11(9):908. doi: 10.3390/jpm11090908. PMID: 34575686.
11. Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, Yeh TJ, Gau YC, **Du JS**, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, Yu ML, Dai CY, Hsiao HH. Poor Prognosis of Diffuse Large

- B-Cell Lymphoma with Hepatitis C Infection. *J Pers Med*. 2021 Aug 27;11(9):844. doi: 10.3390/jpm11090844. PMID: 34575621.
12. Du JS, Kuo YC, Shi HY, Wang MC, Wang LY, Chuang TM, Ke YL, Yeh TJ, Gau YC, Wang HC, Cho SF, Hsiao SY, Liu YC, Hsu CM, Hsiao HH. The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. *J Pers Med*. 2022 Jan 19;12(2):130. doi: 10.3390/jpm12020130. PMID: 35207619; PMCID: PMC8880219.
 13. Yeh TJ, Luo CW, Du JS, Huang CT, Wang MH, Chuang TM, Gau YC, Cho SF, Liu YC, Hsiao HH, Chen LT, Pan MR, Wang HC, Moi SH. Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer. *Biomedicines*. 2023 Feb 24;11(3):691. doi: 10.3390/biomedicines11030691. PMID: 36979671; PMCID: PMC10044978.
 14. Wang HC, Moi SH, Chan LP, Wu CC, Du JS, Liu PL, Chou MC, Wu CW, Huang CJ, Hsiao HH, Pan MR, Chen LT. The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy. *Exp Mol Med*. 2023 May;55(5):926-938. doi: 10.1038/s12276-023-00984-4. Epub 2023 May 1. PMID: 37121970; PMCID: PMC10238468.
 15. Fang WC, Du JS, Su YC, Chiu LW, Yang TT. M2 Polarization May Contribute to Formation of Granulomatous Dermatitis in Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia. *Dermatol Pract Concept*. 2023 Oct 1;13(4):e2023241. doi: 10.5826/dpc.1304a241. PMID: 37992346; PMCID: PMC10656156.
 16. Yeh TJ, Luo CW, Du JS, Huang CT, Wang MH, Chuang TM, Gau YC, Cho SF, Liu YC, Hsiao HH, Chen LT, Pan MR, Wang HC, Moi SH. Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer. *Biomedicines*. 2023 Feb 24;11(3):691. doi: 10.3390/biomedicines11030691. PMID: 36979671; PMCID: PMC10044978.
 17. Huang CT, Lee CP, Chen TY, Liu YC, Cho SF, Du JS, Yu ML, Huang CF, Wang SF, Hsiao HH. Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies. *J Clin Med*. 2023 Aug 30;12(17):5647. doi: 10.3390/jcm12175647. PMID: 37685720; PMCID: PMC10488979.

林家宏醫師

學歷：國立臺灣大學醫學系
國立臺灣大學臨床醫學研究所碩士

資歷：臺大醫院內科住院醫師
臺大醫院新陳代謝內分泌科總醫師
臺大醫院新竹分院新陳代謝內分泌科主治醫師
新竹臺大分院生醫醫院竹北院區新陳代謝內分泌科主治醫師



現職：臺大醫院新陳代謝內分泌科主治醫師
新竹臺大分院生醫醫院竹北院區新陳代謝內分泌科兼任主治醫師
中華民國內分泌暨糖尿病學會官方雜誌 Formosan Journal of Endocrinology and Metabolism (FJEM) 執行編輯

專科證書：中華民國內科專科醫師、中華民國新陳代謝內分泌科專科醫師

論文發表：

1. **Lin CH**, Lin CH, Chung MC, Hung CS, Tseng FY, Er LK, Hou JY, Lin YH, Wu VC, Cheng HM, Kao HL, Wu KD, Lai TS. Aldosterone-to-renin ratio (ARR) as a screening tool for primary aldosteronism (PA). **Journal of the Formosan Medical Association**. 2023 May 10;S0929-6646(23)00145-6.
2. Yen IW, Kuo CH, Lin MW, Tai YY, Chen KY, Chen SC, **Lin CH**, Hsu CY, Lee CN, Lin SY, Li HY, Fan KC. **Journal of the Formosan Medical Association**. 2023 Dec 14;S0929-6646(23)00479-5. Advanced maternal age-related clustering of metabolic abnormalities is associated with risks of adverse pregnancy outcomes.
3. Chen SC, Fan KC, Yen IW, Yang CY, **Lin CH**, Hsu CY, Lyu YP, Juan HC, Lin HH, Lin MS, Shih SR, Li HY, Kuo CH. Serum Vascular Adhesion Protein-1 is Associated with Twelve-year Risk of Incident Cancer, Cancer Mortality, and All-cause Mortality: a Community-based Cohort Study. **Front. Oncol. Sec. Cancer Epidemiology and Prevention** Volume 13 - 2023 | doi: 10.3389/fonc.2023.1308353
4. Tseng HH, Lin YB, Lin KY, **Lin CH**, Li HY, Chang CH, Tung YC, Chen PL, Wang CY, Yang WS, Shih SR. A Twenty-year Study of Autoimmune Polyendocrine Syndrome Type II and III in Taiwan. **European Thyroid Journal**. 2023 Oct 1;ETJ-23-0162
5. Lin KY, Kuo YT, Cheng MF, Chen PL, Wang HP, Cheng TY, Chang CH, Kao HF, Yang SH, Li HY, **Lin CH**, Chou YT, Chung AK, Wu WC, Lu JY, Wang CY, Hsieh WH, Wen CY, Yang WS, Shih SR. Traits of Patients with Pituitary Tumors in Multiple Endocrine Neoplasia Type 1 and Comparing Different Mutation Status. **Journal of Clinical Endocrinol and Metabolism**. 2023 Jun 30; doi: 10.1210/clinem/dgad387
6. Chen SC, Lee CN, Hu FC, Kuo CH, Lin MW, Chen KY, Tai YY, **Lin CH**, Yen IW, Lin SY, Li HY. Gestational hypertriglyceridemia and adverse pregnancy outcomes: A search for cutoffs using generalized additive models. **Diabetes Research and Clinical Practice**. 2022 Apr;186:109820.
7. Chang CF, Yang MH, Lee JH, Shih SR, **Lin CH**, Chen CP, Wu CE, Lu JY. The impact of BRAF

- targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan. **American Journal of Cancer Research**. 2022 Nov 15;12(11):5342-5350.
8. **Lin CH**, Wei JN, Fan KC, Fang CT, Wu WC, Yang CY, Lin MS, Shih SR, Hua CH, Hsein YC, Lin JW, Chuang LM, Li HY. Different cutoffs of hypertension, risk of incident diabetes and progression of insulin resistance: A prospective cohort study. **Journal of Formosan Medical Association**. 2022 Jan;121(1 Pt 1):193-201.
 9. Wu WC, Wei JN, Chen SC, Fan KC, **Lin CH**, Yang CY, Lin MS, Shih SR, Hua CH, Hsein YC, Chuang LM, Li HY. Progression of insulin resistance: A link between risk factors and the incidence of diabetes. **Diabetes Research and Clinical Practice**. 2020 Feb 5;161:108050.
 10. **Lin CH**, Chang CK, Shih CW, Li HY, Chen KY, Yang WS, Tsai KS, Wang CY, Shih SR. Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study. **Osteoporosis International**. 2019 Nov;30(11):2289-2297.
 11. Yen IW, Lee CN, Lin MW, Fan KC, Wei JN, Chen KY, Chen SC, Tai YY, Kuo CH, **Lin CH**, Hsu CY, Chuang LM, Lin SY, Li HY. Overweight and obesity are associated with clustering of metabolic risk factors in early pregnancy and the risk of GDM. **PLoS One**. 2019 Dec 3;14(12):e0225978.
 12. **Lin CH** (equal first author), Chen KH, Chen KY, Shih SR, Lu JY. Immune checkpoint inhibitor therapy-induced hypophysitis ~ a case series of Taiwanese patients. **Journal of Formosan Medical Association**. 2019 Jan;118(1 Pt 3):524-529.
 13. **Lin CH**, Wei JN, Lin MS, Shih SR, Hua CH, Hsien YC, Li HY. Interaction Between Pancreatic β -cell Dysfunction and Insulin Resistance on the Incidence of Diabetes Mellitus. **Formosan Journal of Endocrinology and Metabolism**. 2017 Jun;8(1): 6-13